According to a Wall Street Journal report, Merck & Co. has halted discussions to acquire cancer‐drug developer Revolution Medicines in what had been a potential transaction valued at roughly $30 billion. The collapse of these talks removes a significant near‐term catalyst for Merck’s oncology pipeline expansion, particularly considering Revolution’s KRAS inhibitor platform that had attracted strategic interest from multiple large biopharma firms. Merck’s decision not to proceed may reflect valuation disagreements or a reassessment of internal R&D priorities, but it also means the company must rely on its existing immuno‐oncology assets, such as Keytruda, and pipeline candidates to drive future growth in its high‐margin cancer therapeutics franchise.

During the most recent quarter, Cullen Frost Bankers Inc. reduced its position in Merck by 7.0%, disposing of 17,082 shares to leave a holding of 225,581 shares valued at $18.9 million as per its SEC filing. In contrast, Charles Schwab Investment Management Inc. increased its stake by 9.4%, acquiring 4.64 million additional shares to reach 53.87 million shares worth $4.26 billion. New entrants included DLD Asset Management LP and Norges Bank, each deploying approximately $2.89 billion and $2.86 billion, respectively, into Merck equity during the quarter. Meanwhile, Franklin Resources Inc. and Fisher Asset Management LLC boosted their holdings by 23.5% and 2.3%, accumulating 27.0 million and 25.0 million shares respectively. Collectively, institutional investors and hedge funds now own over 76% of Merck’s outstanding stock, underscoring strong long‐term confidence despite the acquisition setback.

In its most recent quarterly report, Merck posted earnings per share of $1.94, falling short of the consensus estimate of $2.08, while achieving a return on equity of 44.5% and net margin of 29.6%. The company also announced a quarterly dividend increase from $0.81 to $0.85 per share, translating to an annualized payout of $3.40 and a yield near 3.1%, and reflecting a payout ratio of 44.9%. On the research front, BMO Capital Markets, Goldman Sachs, Scotiabank, Bank of America and Wolfe Research collectively lifted their price targets into the $120–$135 range, though the consensus rating remains at “Hold.” Analyst commentary highlights both Merck’s robust free cash flow profile supporting returns to shareholders and the need for pipeline visibility beyond Keytruda to justify higher valuations.